-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:KLAC第三季度业绩略超预期,营收为34.2亿美元(同比增长11%),高于市场普遍预期的33.8亿美元;非GAAP每股收益为9.40美元(同比增长12%),高于市场普遍预期的9.17美元;毛利率为62.2%,高于KLAC此前给出的61.75%的预期中值。半导体过程控制业务(占销售额的90%)同比增长13%,高于去年12月季度的9%,反映出人工智能业务的持续强劲增长。令人欣喜的是,尽管KLAC将其在中国的业务占比降至24%(环比下降600个基点),但其业绩仍然超出预期。管理层预计6月季度销售额约为35.75亿美元(接近市场预期),2026财年增长率将达到两位数以上,高于15%的市场普遍预期。令人意外的是,管理层还预测2027财年增长率将超过2026财年(同样高于15%的市场普遍预期),这反映出前所未有的业绩可预测性。KLAC预计,受高企的内存价格影响,未来利润率将面临100个基点的下行压力,但仍对确保必要的供应充满信心。逻辑电路客户的销售额预计将在第四季度达到82%,高于第三季度的62%,但我们仍然预计内存客户的贡献将在未来几个季度继续增长。
Related Articles
Electro Optic Systems Reports Contract Backlog Growth as of March 31
Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.
Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance
Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.